Riskpilot← Back to searchSign inGet full accessPauci Medtech Consulting AB
ABActiveOrg 5568644065Torggatan 2 1trWholesale of pharmaceutical and medical goods · NACE 4646Est. 20111 employees
Revenue 2024
SEK 0
EBITDA margin
—
-101% vs 2023
Equity ratio
75.0%
Financial strength
Net profit 2024
SEK 10K
-80% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -294K | -101% |
| Net profit | SEK 10K | -80% |
| Total assets | SEK 2,3M | -30% |
| Equity | SEK 1,7M | -13% |
| Employees | 1 | — |
Legal name
Pauci Medtech Consulting AB
Org number
5568644065
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 september 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall huvudsakligen ägna sig åt tjänsteförsäljning av försäljnings samt ledningstjänster inom medicintekniska branschen och därmed förenlig verksamhet.
Address
Torggatan 2 1tr
Email
magnus.broddesson@spoxmed.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 674 | 5 023 | 2 965 | 107 | 0 |
| Staff expenses | — | — | — | −587 | −171 |
| EBITDA | 648 | 832 | 2 753 | −146 | −294 |
| Depreciation & amort. | −23 | −23 | −0 | — | — |
| EBIT | 625 | 809 | 2 753 | −146 | −294 |
| Net financials | −2 | −1 | 11 | 49 | 29 |
| Profit before tax | 491 | 856 | 2 325 | 72 | 25 |
| Tax | −108 | −179 | −490 | −21 | −14 |
| Net profit | 383 | 677 | 1 835 | 52 | 10 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 097 | 2 454 | 4 146 | 3 207 | 2 260 |
| Equity | 941 | 1 317 | 2 552 | 1 946 | 1 696 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 550 | 579 | 596 | 433 | 26 |
| Total debt | 550 | 579 | 596 | 433 | 26 |
EBITDA margin
-29401600.0%
This company
15.8%
Market median
-186086176% vs market
20202024
Equity ratio
75.0%
This company
38.2%
Market median
+96% vs market
20202024
Return on equity
0.6%
This company
18.4%
Market median
-97% vs market
20202024
Net profit margin
1022700.0%
This company
8.1%
Market median
+12625826% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LM Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
BN | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pauci Medtech Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Niclas Valdemar Frank | Audit | 0 companies |
| Lars Magnus Broddesson | Chief Executive Officer | 0 companies |
| Susanne Ann-Louise Broddesson | Board of Directors | 0 companies |
| Nils Berne Jönsson | Chairman | 0 companies |